Skip to main content

Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial

Publication ,  Conference
Chonat, S; Grace, R; Dickerson, K; Andres, O; Bartels, M; Beynon, V; Despotovic, J; Glader, B; Huguenin, Y; Kwiatkowski, J; Laflam, E; Yin, O ...
Published in: Blood
November 3, 2025

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 3, 2025

Volume

146

Issue

Supplement 1

Start / End Page

4654 / 4654

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chonat, S., Grace, R., Dickerson, K., Andres, O., Bartels, M., Beynon, V., … Sevilla, J. (2025). Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial. In Blood (Vol. 146, pp. 4654–4654). American Society of Hematology. https://doi.org/10.1182/blood-2025-4654
Chonat, Satheesh, Rachael Grace, Kathryn Dickerson, Oliver Andres, Marije Bartels, Vanessa Beynon, Jenny Despotovic, et al. “Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial.” In Blood, 146:4654–4654. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-4654.
Chonat, Satheesh, et al. “Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 4654–4654. Crossref, doi:10.1182/blood-2025-4654.
Chonat S, Grace R, Dickerson K, Andres O, Bartels M, Beynon V, Despotovic J, Glader B, Huguenin Y, Kwiatkowski J, Laflam E, Rivadeneyra L, McGee B, Yin O, Murciano Carrillo T, Pastore Y, Rothman J, Tyler P, Xu E, Renella R, Sevilla J. Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial. Blood. American Society of Hematology; 2025. p. 4654–4654.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 3, 2025

Volume

146

Issue

Supplement 1

Start / End Page

4654 / 4654

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology